Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. (Q38195336)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

review article

1 reference

title

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Joaquim Gascón

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

María del Carmen Thomas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Manuel Carlos López

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Jacqueline Bua

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alina Perrone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alejandro-Gabriel Schijman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Rodolfo-Jorge Viotti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Janine-M Ramsey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Isabela Ribeiro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sergio Sosa-Estani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

479-496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24621252%20AND%20SRC:MED&resulttype=core&format=json

Chagas disease in Spain, the United States and other non-endemic countries

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Chagas disease: a Latin American health problem becoming a world health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Global economic burden of Chagas disease: a computational simulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Evaluation and treatment of chagas disease in the United States: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Where do we stand on the autoimmunity hypothesis of Chagas disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

A critical review on Chagas disease chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Benzonidazole therapy modulates interferon-γ and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Chagas disease: recombinant Trypanosoma cruzi antigens for serological diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Multiple Trypanosoma cruzi antigens containing tandemly repeated amino acid sequence motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Brain natriuretic peptide in Chagas' disease: further insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Serum NT pro-BNP: relation to systolic and diastolic function in cardiomyopathies and pericardiopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Leptin levels in different forms of Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Positive troponin T in a chagasic patient with sustained ventricular tachycardia and no obstructive lesions on cine coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

The adipocyte as an important target cell for Trypanosoma cruzi infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Enhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: implications in Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Biomarker discovery in serum/plasma using surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Hypercoagulability biomarkers in Trypanosoma cruzi-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Monitoring the efficacy of specific treatment in chronic Chagas disease by polymerase chain reaction and flow cytometry analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Chagas disease in Latin American migrants: a Spanish challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Biomarkers and surrogate markers: an FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Potential use of synthetic α-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150

Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.899150